Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: Results from a randomized double-blind placebo-controlled, phase II trial

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 12, 2012, Pages 1516-1521

  Bissonnette, R ^a   Bolduc, C ^a   Maari, C ^a   Nigen, S ^a   Webster, J M ^b   Tang, L ^b   Lyle, M ^b  

^a INNOVADERM RESEARCH   (Canada)

^b Welichem Biotech Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 ISOPROPYL 5 (2 PHENYLETHENYL)BENZENE 1,3 DIOL; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; UNCLASSIFIED DRUG; WBI 1001;

ABDOMINAL PAIN; ADULT; AGED; APPLICATION SITE BURNING; APPLICATION SITE DISCOLORATION; APPLICATION SITE FOLLICULITIS; APPLICATION SITE PAIN; APPLICATION SITE PAPULE; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; ARTICLE; BACKACHE; BODY SURFACE; CONTACT DERMATITIS; CONTROLLED STUDY; CREAM; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRY SKIN; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PHASE 2 CLINICAL TRIAL; PHYSICIAN GLOBAL ASSESSMENT SCORE; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS;

ADMINISTRATION, TOPICAL; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; HUMANS; PLACEBOS; PSORIASIS; RESORCINOLS; SEVERITY OF ILLNESS INDEX; STILBENES;

EID: 84869487969     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04332.x     Document Type: Article

References (9)

1. Greaves MW, Weinstein GP,. Treatment of psoriasis. N Engl J Med 1995; 332: 581-588.
2. Bos JD, Spuls PI,. Topical treatment in psoriasis: today and tomorrow. Clin Dermatol 2008; 26: 432-437.
3. Gottlieb AB,. Psoriasis: emerging therapeutic strategies. Nat Rev Drug Discov 2005; 4: 19-34.
4. Lowes MA, Bowcock AM, Krueger JG,. Pathogenesis and therapy of psoriasis. Nature 2007; 445: 866-873.
5. Mechanism of action of WBI-1001. Unpublished raw data, Welichem Biotech Inc, Burnaby, British Columbia, Canada.
6. Bissonnette R, Chen G, Bolduc C, et al. Efficacy and safety of topical WBI-1001 in the treatment of atopic dermatitis: results from a phase 2A, randomized, placebo-controlled clinical trial. Arch Dermatol 2010; 146: 446-449.
7. Feldman SR, Krueger GG,. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2006; 64: 65-68.
8. Feldman SR, Fleischer AB Jr, Reboussin DM, et al. The self-administered psoriasis area and severity index is valid and reliable. J Invest Dermatol 1996; 106: 183-186.
9. Fleming C, Ganslandt C, Guenther L, et al. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study. Eur J Dermatol 2010; 20: 465-471.